MD Medical Group opens new clinic in Vladimir
|Download file (220 K)|
MD Medical Group Investments Plc (“MD Medical Group”, “MDMG” or the “Company” – LSE: MDMG), a leading Russian private healthcare provider, announces that it has opened a new clinic in Vladimir.
The clinic was opened in response to high demand for the services offered by the Group’s first clinic in the city, which opened in January 2017. A new – significantly bigger – clinic is now replacing the first one. Compared to its predecessor, which operated out of a leased facility in a municipal healthcare institution, the new clinic offers its patients enhanced comfort and improved transport accessibility.
The new Mother and Child Vladimir clinic has 354 sq m of space and is equipped with state-of-the-art medical equipment. It offers a wider range of the Company’s core healthcare services, including IVF, ultrasound, minor gynaecological operations in the day-patient centre, OBGYN consultations, and foetal medicine services. The clinic also includes an embryology laboratory. Other specialists on-site include primary care doctors, endocrinologists, andrologists, and more. In total, the clinic employs 20 doctors.
The clinic has a capacity for up to 400 minor gynaecological operations, 500 IVF cycles (including cycles under the MHI programme), and 15,000 consultations with doctors each year.
Mother and Child Vladimir operates to MD Medical Group’s customary high standards of medical care.
Total investment in the project amounted to 30 million roubles.
Mark Kurtser, CEO of MD Medical Group, said:
“In January 2017, we opened our first clinic in the Vladimir Region. The past year has demonstrated that our decision to enter a new region was beneficial. The clinic has gained a solid reputation among local residents who have received access to high-technology healthcare where they live. Our services have been in high demand and thus we decided to launch a new clinic – much bigger and offering more services. And where previously patients had to visit our clinic in Yaroslavl to complete the second stage of IVF, now the whole cycle will take place within one clinic.“In addition to IVF and our other core services for women, the clinic’s offering will include endocrinology, andronology, and other specialties. This reflects our business development strategy – a focus on specialised services for women and children with a gradual expansion in the range and volume of services we offer the whole family.”
For further information please contact:
MD Medical Group Investments Plc
Tel: +7 495 331 4120
Tom Blackwell: +7 919 102 9064
Sergii Pershyn: +1 929 855 8188
About MD Medical Group
MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. The company manages 34 modern healthcare facilities, including 4 hospitals and 30 outpatient clinics in Moscow and the Moscow Region, St. Petersburg, Ufa, Perm, Samara and the Samara Region, Irkutsk, Novosibirsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, Tyumen, and Voronezh.
The Company’s shares have been listed on the London Stock Exchange (LSE ticker “MDMG”) in the form of Global Depositary Receipts (GDRs) since 12 October 2012.
This press release contains forward looking statements, which are based on the Company’s current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company’s ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.
No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.
2018 2017 2016 2015 2014 2013 2012